针对 COVID-19 的 COVISHIELD 和 VERO CELL 疫苗接种活动引发的不良事件。

Q3 Medicine
Santosh Adhikari, Jessica Maharjan, Sushan Bhattarai, Kshitij Kunwar, Sumit Agrawal, Raj Kumar Dangal, Ram Hari Chapagain, Tek Bahadur Bista, Srijana Bhattarai
{"title":"针对 COVID-19 的 COVISHIELD 和 VERO CELL 疫苗接种活动引发的不良事件。","authors":"Santosh Adhikari, Jessica Maharjan, Sushan Bhattarai, Kshitij Kunwar, Sumit Agrawal, Raj Kumar Dangal, Ram Hari Chapagain, Tek Bahadur Bista, Srijana Bhattarai","doi":"10.33314/jnhrc.v21i4.4926","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Vaccination against COVID-19 for Nepalese was initiated in January 2021 for various age groups. People were anxious about receiving the vaccines and were concerned about the safety profile of the vaccine they received. In this study, we have tried to observe the Adverse Events Following Immunization of two different vaccines namely COVISHIELD (ChAdOx1 nCOV-19) and VERO CELL (CZ02 strain), used in different phases of vaccination by the government of Nepal.</p><p><strong>Methods: </strong>We conducted a cross-sectional study among people who received COVID-19 vaccines in this study using a self-administered questionnaire.  Data was cleaned and then exported to IBM SPSS v.20 for analysis, Chi-square test was used to see the association between different variables and a p-value<0.05 was considered statistically significant.</p><p><strong>Results: </strong>Out of 303 respondents, all had received the first and 270 participants had received the second dose of the COVID-19 vaccine, among which, 133 (43.89%) reported at least one side effect after the first dose of vaccination while 58 (21.48%) had self-reported side effects after the second dose of vaccination. Seventeen percent of the respondents had COVID-19 infection within the past 3 months before receiving COVID-19 vaccine. Three percent of participants had re-infection with COVID-19 after receiving the first or the second dose of the COVID-19 vaccine. Among participants who experienced adverse events, 42% and 62.1% of participants experienced mild adverse events following the first dose and second dose of the vaccine, respectively.  Conclusions: The adverse events following immunization for both vaccines after both doses of vaccination were quite low, with 43.89% of participants reporting side effects after the first dose and 21.48% of participants reporting side effects after the second dose. Adverse events were most frequently reported within 24 hours of vaccination and were mostly mild. There was no statistical significance of adverse events between both vaccines.</p>","PeriodicalId":16380,"journal":{"name":"Journal of Nepal Health Research Council","volume":"21 4","pages":"651-658"},"PeriodicalIF":0.0000,"publicationDate":"2024-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Adverse Events Following COVISHIELD and VERO CELL Vaccination Campaigns Against COVID-19.\",\"authors\":\"Santosh Adhikari, Jessica Maharjan, Sushan Bhattarai, Kshitij Kunwar, Sumit Agrawal, Raj Kumar Dangal, Ram Hari Chapagain, Tek Bahadur Bista, Srijana Bhattarai\",\"doi\":\"10.33314/jnhrc.v21i4.4926\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Vaccination against COVID-19 for Nepalese was initiated in January 2021 for various age groups. People were anxious about receiving the vaccines and were concerned about the safety profile of the vaccine they received. In this study, we have tried to observe the Adverse Events Following Immunization of two different vaccines namely COVISHIELD (ChAdOx1 nCOV-19) and VERO CELL (CZ02 strain), used in different phases of vaccination by the government of Nepal.</p><p><strong>Methods: </strong>We conducted a cross-sectional study among people who received COVID-19 vaccines in this study using a self-administered questionnaire.  Data was cleaned and then exported to IBM SPSS v.20 for analysis, Chi-square test was used to see the association between different variables and a p-value<0.05 was considered statistically significant.</p><p><strong>Results: </strong>Out of 303 respondents, all had received the first and 270 participants had received the second dose of the COVID-19 vaccine, among which, 133 (43.89%) reported at least one side effect after the first dose of vaccination while 58 (21.48%) had self-reported side effects after the second dose of vaccination. Seventeen percent of the respondents had COVID-19 infection within the past 3 months before receiving COVID-19 vaccine. Three percent of participants had re-infection with COVID-19 after receiving the first or the second dose of the COVID-19 vaccine. Among participants who experienced adverse events, 42% and 62.1% of participants experienced mild adverse events following the first dose and second dose of the vaccine, respectively.  Conclusions: The adverse events following immunization for both vaccines after both doses of vaccination were quite low, with 43.89% of participants reporting side effects after the first dose and 21.48% of participants reporting side effects after the second dose. Adverse events were most frequently reported within 24 hours of vaccination and were mostly mild. There was no statistical significance of adverse events between both vaccines.</p>\",\"PeriodicalId\":16380,\"journal\":{\"name\":\"Journal of Nepal Health Research Council\",\"volume\":\"21 4\",\"pages\":\"651-658\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-03-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Nepal Health Research Council\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.33314/jnhrc.v21i4.4926\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Nepal Health Research Council","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33314/jnhrc.v21i4.4926","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

背景:尼泊尔于 2021 年 1 月开始为不同年龄段的人接种 COVID-19 疫苗。人们对接种疫苗感到焦虑,并担心所接种疫苗的安全性。在本研究中,我们试图观察两种不同疫苗(即 COVISHIELD (ChAdOx1 nCOV-19) 和 VERO CELL (CZ02 株))的免疫接种后不良事件:我们采用自填问卷的方式对接种 COVID-19 疫苗的人群进行了横断面研究。 数据经过清理后导出到 IBM SPSS v.20 中进行分析,并使用卡方检验(Chi-square test)来检验不同变量之间的关联性和 p 值:在 303 名受访者中,所有受访者都接种了第一剂 COVID-19 疫苗,270 人接种了第二剂,其中 133 人(43.89%)报告在接种第一剂疫苗后至少出现了一种副作用,58 人(21.48%)自述在接种第二剂疫苗后出现了副作用。17%的受访者在接种COVID-19疫苗前的3个月内感染过COVID-19。3%的受访者在接种第一剂或第二剂COVID-19疫苗后再次感染了COVID-19。在出现不良反应的参与者中,分别有42%和62.1%的人在接种第一剂和第二剂疫苗后出现轻微不良反应。 结论:两种疫苗在两剂接种后的不良反应都很低,43.89%的参与者在第一剂接种后报告了副作用,21.48%的参与者在第二剂接种后报告了副作用。不良反应多发生在接种后 24 小时内,且大多较轻。两种疫苗的不良反应没有统计学意义。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Adverse Events Following COVISHIELD and VERO CELL Vaccination Campaigns Against COVID-19.

Background: Vaccination against COVID-19 for Nepalese was initiated in January 2021 for various age groups. People were anxious about receiving the vaccines and were concerned about the safety profile of the vaccine they received. In this study, we have tried to observe the Adverse Events Following Immunization of two different vaccines namely COVISHIELD (ChAdOx1 nCOV-19) and VERO CELL (CZ02 strain), used in different phases of vaccination by the government of Nepal.

Methods: We conducted a cross-sectional study among people who received COVID-19 vaccines in this study using a self-administered questionnaire.  Data was cleaned and then exported to IBM SPSS v.20 for analysis, Chi-square test was used to see the association between different variables and a p-value<0.05 was considered statistically significant.

Results: Out of 303 respondents, all had received the first and 270 participants had received the second dose of the COVID-19 vaccine, among which, 133 (43.89%) reported at least one side effect after the first dose of vaccination while 58 (21.48%) had self-reported side effects after the second dose of vaccination. Seventeen percent of the respondents had COVID-19 infection within the past 3 months before receiving COVID-19 vaccine. Three percent of participants had re-infection with COVID-19 after receiving the first or the second dose of the COVID-19 vaccine. Among participants who experienced adverse events, 42% and 62.1% of participants experienced mild adverse events following the first dose and second dose of the vaccine, respectively.  Conclusions: The adverse events following immunization for both vaccines after both doses of vaccination were quite low, with 43.89% of participants reporting side effects after the first dose and 21.48% of participants reporting side effects after the second dose. Adverse events were most frequently reported within 24 hours of vaccination and were mostly mild. There was no statistical significance of adverse events between both vaccines.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
1.40
自引率
0.00%
发文量
81
审稿时长
15 weeks
期刊介绍: The journal publishes articles related to researches done in the field of biomedical sciences related to all the discipline of the medical sciences, medical education, public health, health care management, including ethical and social issues pertaining to health. The journal gives preference to clinically oriented studies over experimental and animal studies. The Journal would publish peer-reviewed original research papers, case reports, systematic reviews and meta-analysis. Editorial, Guest Editorial, Viewpoint and letter to the editor are solicited by the editorial board. Frequently Asked Questions (FAQ) regarding manuscript submission and processing at JNHRC.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信